Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma

Figure 2 Recommended hepatocellular carcinoma screening approach in nonalcoholic fatty liver disease/nonalcoholic steatohepatitis patients according to the risk category. AASLD: the American Association for the Study of Liver Diseases; AFP: Alpha-fetoprotein; AGA: American Gastroenterology Association; EASL: The European Association for the Study of the Liver; FIB-4: Fibrosis-4; HCC: Hepatocellular carcinoma; LSM: Liver stiffness measurement; NASH: Nonalcoholic steatohepatitis; MRE: Magnetic resonance elastography; US: Ultrasonography.